Richard Knox

America's oldest citizens are generally getting healthier, living longer and doing better financially. But there's lots of room for improvement.

That's the take-home from an exhaustive picture of Americans over 65 put together by the federal government and released last week during the summer doldrums.

A month ago the results of a successful cholera vaccine project in Haiti became available. Now the World Health Organization is calling for the establishment of a global stockpile of the vaccine to respond to outbreaks like Haiti's.

Dr. Rochelle Walensky thinks the 19th International AIDS Conference will be remembered as the moment when the world began to mobilize to end the pandemic.

The Harvard researcher probably speaks for many of the 23,000 scientists, activists and policy mavens who came to the Washington conference. But they're going home with a big question on their minds: Can the world afford it?

The big question hanging over the International AIDS Conference this week is whether all 34 million people in the world with HIV can possibly get antiviral drug treatment.

There's a lot of buzz at the 19th International AIDS Conference about powerful new strategies to prevent HIV infection.

But a potent old strategy isn't used enough around the world, many researchers say, and is even neglected entirely in places where it's most urgently needed.

It's called needle exchange.

If you show up at the emergency department at San Francisco General Hospital — for any reason — there's a good chance they'll offer you an HIV test.

It's part of a big push, in a city closely associated with the AIDS pandemic, to find nearly all people infected with the virus and get them in treatment right away.

The results are in on this spring's high-visibility pilot project to vaccinate 100,000 Haitians against cholera.

Almost 90 percent of the target population – half in Port-au-Prince and the other half in a remote rural area – got fully protected against cholera, meaning they got 2 doses of the oral vaccine.

The results defy the forecasts of skeptics who said in advance of the campaign that it would be lucky to protect 60 percent of the target populations.

There's something new to prevent HIV infections.

The Food and Drug Administration on Monday approved a once-a-day pill that can drastically lower a person's risk of getting the virus that causes AIDS.

It's called Truvada — the first HIV prevention pill.

It's not cheap — around $13,000 a year — and it's not clear what insurers will pay for it. And there's worry that people taking the pill might relax safe-sex precautions.